News & blog

Redx celebrates breakthrough antibiotics development

CHESHIRE drug development company Redx Pharma has developed a series of compounds which have successfully completed two vivo infection studies which show the programme has the potential to create the first new class of broad spectrum antibiotics in 30 years.

The research, conducted by Redx at its facilities at Alderley Park, Cheshire, found the compounds are highly effective against a range of drug resistant bacteria including Gram negative species such as E. coli and Pseudomonas which can be responsible for drug resistant forms of pneumonia, urinary tract infections, intra-abdominal infections and septicaemia.

In the in vivo study, using a multi-drug resistant strain of bacteria, the lead compound achieved a significant decrease in bacterial infection levels which was equivalent to tigecycline, a current drug-of-last-resort used in treating antibiotic resistant bacteria. Read More